- Lead peptide JEL3108 shows efficacy in inflammatory disease tissue
- Significant changes seen in atopic dermatitis (AD, eczema) and burn tissue biopsies
- Indicates potential to prevent scarring and help treat other inflammation-related skin indications
Cheadle, UK – 10 January 2022 – Today, Carocell Bio, the anti-inflammation therapeutics company, announced that its lead anti-inflammatory peptide JEL3108 shows efficacy in human inflammatory disease tissue biopsies. The candidate peptide-based treatment provides an innovative approach to reduce pain and prevent scar formation after a burn and after surgery, through a novel, next-generation anti-inflammatory MAP kinase-inhibiting mechanism. It can also potentially be used to treat severe burns and chronic skin conditions such as atopic dermatitis.
The preclinical tests are being carried out in collaboration with the world-leading surgeon and researcher Professor Fadi Issa, Associate Professor of Burns and Plastic Surgery at the University of Oxford and Consultant Plastic Surgeon, Buckinghamshire Healthcare NHS Trust. In December 2022, the company announced fundraising of USD $500,000 (£GBP 404,000) from Deepbridge Capital to support pre-clinical testing of JEL3108 for skin-related indications.
Carocell Bio’s CEO, Dr Mike Davies, said:
“These data demonstrate the potential of our anti-inflammatory peptide approach to help prevent scarring and potentially be used for other indications where inflammation plays a role. Applied topically, our novel MAP kinase inhibitory peptides could therefore make a positive and lasting change in patients’ lives. We are now focused on generating further preclinical data to help support our current findings.”
This week, Mike Davies will be in San Francisco for the 41st annual JP Morgan Healthcare Conference (9-12 January), as well as other meetings that week, including RESI San Francisco 2023 (11 January) and Dermatology Summit 2023 (8 January). Contact Mike at email@example.com to learn more about Carocell Bio or set up a meeting.